Odyssey Therapeutics is a pre-revenue biotech with widening losses and below-floor quality, offset by strong analyst upside, improving volume-led momentum and very positive news sentiment.
Thesis pillars
- No Revenue Quality Below Floor→Stable
- Large Analyst Upside→Stable
- Losses Worse Than Estimates↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026
Odyssey Therapeutics, Inc. (ODTX) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $19.54: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 3.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for... Read more
Sell if holding. Engine safety override at $19.54: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 3.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 59 mid-range, Bollinger mid-band. Score 5.5/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 7d<=7d. Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — Odyssey Therapeutics, Inc.
Latest news
- NEWS Odyssey Therapeutics Announces Positive Phase 2a Results for OD-001 in Ulcerative Colitis — fiscal.ai Oct 20, 2026 positive
- NEWS Odyssey Therapeutics Reports 27% Clinical Remission At 20mg In Phase 2a Ulcerative Colitis Trial Of OD-001, Meets Primar — benzinga Oct 20, 2026 positive
- NEWS UBS Initiates Coverage On Odyssey Therapeutics with Buy Rating, Announces Price Target of $27 — benzinga Oct 12, 2026 positive
- NEWS Odyssey Therapeutics To Present Design Of Randomized, Double-Blind Phase 2a Trial Evaluating OD-001 In Combination With — benzinga Oct 12, 2026 neutral
- NEWS Raymond James Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $42 — benzinga Oct 9, 2026 positive
Generated 2026-10-29T11:14:34Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $19.54: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.5/10 and A.R:R 3.8:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 59 mid-range, Bollinger mid-band. Prior stop was $18.17. Score 5.5/10, moderate confidence.
Analyst target: $30.74 (+57.3% upside). Prior stop was $18.17. Stop-loss: $18.17.
Quality below floor (3.0 < 4.0).
Odyssey Therapeutics, Inc. trades at a P/E of N/A (forward -4.5). TrendMatrix value score: 9.0/10. Verdict: Sell.
12 analysts cover ODTX with a consensus score of 4.3/5. Average price target: $35.
What does Odyssey Therapeutics, Inc. do?Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and...
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.